EverHint — Pullback Plays (with Insider Overlay) - October 29, 2025
October 29, 2025
What “Pullback Plays” means (quick refresher)
A pullback is a temporary dip inside a clear uptrend—often toward rising 21-/50-day MAs. The best setups: resilient RS, constructive volume, and shallow/mid pullbacks that respect support.
How today’s list was curated (reader version)
I prioritized names that:
- Sit near rising support (distance to 21d/50d MAs)
- Hold high proximity to 52-week highs with solid short-term RS
- Show supportive participation (volume thrust)
- Have insider flow context (net open-market buys vs. sells)
Top Pullback Candidates (ranked)
| Rank | Ticker | Company | Sector | Last | Near 52-W High | RS (21 d) | Vol Thrust | Dist. to 21d MA | Dist. to 50d MA | Pullback Depth | Insider Net (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | GSK | GSK plc | Healthcare | 45.93 | 99% | 0.03 | 2.22× | +4.3% | +9.8% | ||
| 2 | ARQT | Arcutis Biotherapeutics, Inc. | Healthcare | 25.29 | 100% | 0.30 | 2.04× | +20.9% | +36.3% | $417,067 |
How to read it
- Dist. to 21d/50d = price vs. the moving average (positive = above MA).
- Vol Thrust > ~1.5× signals broad participation.
- Insider Net (USD) = net open-market buys − sells (positive = supportive, negative = headwind).
Carlo’s quick reasoning
- GSK — Classic “shallow pullback within leadership”: near 52-week highs (99%), above the 21d (+4.3%) with 2.22× participation. Fresh Q3 print raised 2025 guidance; shares reacted well, underpinning the trend. (GSK)
- ARQT — Momentum name at 100% of highs with 2.04× thrust and positive net insider flow (~$417k) in your file. The company posted first-ever positive net income and accelerating ZORYVE growth; stock surged on results. Technically extended vs. 21d/50d, so favor flags/sideways digestion for entries. (Arcutis Biotherapeutics)
Same-day / recent headlines to watch (canonical links)
- GSK — “Delivers strong Q3 performance and upgrades 2025 guidance.” Official press release + slide deck. (GSK)
- ARQT — “Strategy for sustainable growth + Q3 2025 results” (company site). Coverage notes first profitable quarter and record revenue trajectory. (Arcutis Biotherapeutics)
On Watch (risk notes)
- Event aftermath: Both names had news-driven strength; expect volatility as the tape digests.
- Extension vs. support: ARQT sits far above the 21d/50d—prefer buying after an orderly flag over chasing highs.
- Insiders: Net positive flow in ARQT is supportive; GSK shows neutral in today’s overlay.
Vlad’s Take
This is a breadth-plus-power day for healthcare. GSK looks like a steady pullback-and-go candidate given raised guidance and strong tape. ARQT has the juice—just wait for a calm setup (tight flag / inside day) to control risk, or scale with tiered entries and ATR-aware stops below recent swing lows.
EverHint — Independent research. No hype, no pumps, no paid promotions — just clean, data-driven signals and concise context.